In the real world, the selection of a therapeutic modality like an antibody or peptide is often driven by a company's existing expertise and technology platform rather than a purely agnostic approach to finding the single best tool for a clinical problem. Organizations default to the tools in their toolbox.

The clinical development plan for Enara's novel therapies is a two-step process. First, establish monotherapy efficacy in late-line patients to get a clear signal. The ultimate goal, however, is to quickly move into earlier lines of therapy in combination with standard of care, where the market opportunity and patient benefit are greatest.

Unlike competitors focusing on specific gamma delta T-cell subtypes, Cytospire's 'pan' approach activates all of them (blood-resident and tumor-resident). This strategy aims to maximize the number and activity of effector cells for a stronger immune response. It also serves as a crucial hedge against patient-to-patient variability in immune cell composition, potentially improving efficacy across a broader population.

CEO Christian Leisner identifies a single decision as a game-changing milestone: focusing their T-cell engagers on "clean but challenging" tumour antigens. He vividly recalls the meeting where this choice set a clear, relevant strategic direction that the company still follows years later.

Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.

Cytospire targets well-validated antigens like EGFR, which were previously 'undruggable' by CD3 engagers due to severe toxicity on healthy cells. Their gamma delta T-cell platform solves this by enabling 'context-dependent killing,' discriminating between tumor and healthy tissue. This safety profile could unlock a portfolio of solid tumor targets previously considered too dangerous for this drug class.

While some firms repurpose cancer T-cell engagers (TCEs), a new wave of innovation is emerging from China. These biotechs are designing novel, "fit-for-purpose" constructs like trispecifics and molecules with co-stimulatory receptors specifically for the unique safety and efficacy demands of autoimmune disease.

While many cell therapies rely on complex genetic engineering with viral vectors, Adaptin Bio manipulates patient T-cells without it. This simpler, non-viral process is a strategic choice to reduce costs, speed up manufacturing, and make the therapy accessible to a broader patient population.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.